Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Global coagulation function under emicizumab with bypassing agents in hemophilia A with inhibitor
jRCTs051190119Completed
- Sponsor
- Not applicable
- Start
- Mar 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Not applicable. Primary endpoint: Improvement in maximum coagulation rate by coagulation waveform analysis. Started Mar 2020; status: completed.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCTs051190119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051190119.